Fatigue News and Research RSS Feed - Fatigue News and Research

Many MEN1 tumour types found in children

Many MEN1 tumour types found in children

Most tumour types reported in adult patients with multiple endocrine neoplasia Type-1 can be found in children with the condition, although rarely before the age of 10 years, shows a large study. [More]
Researchers receive $2.2M grant to study links between depression and cardiovascular disease in HIV patients

Researchers receive $2.2M grant to study links between depression and cardiovascular disease in HIV patients

Jesse Stewart, Ph.D., associate professor of psychology in the School of Science at Indiana University-Purdue University Indianapolis, and two colleagues have received a $2.2 million National Institutes of Health grant to investigate the links between depression, depression treatment and cardiovascular disease in adults with HIV. [More]
Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Patients with anaplastic lymphoma kinase-rearranged non-small-cell lung cancer who have leptomeningeal metastases may benefit from treatment with the second-generation ALK inhibitor alectinib, a case series suggests. [More]
Study shows that some older women with breast cancer could avoid radiotherapy

Study shows that some older women with breast cancer could avoid radiotherapy

Some older women with breast cancer could safely avoid radiotherapy, without harming their chances of survival, a study has shown. [More]
New article provides insight into cognitive fatigue in people with multiple sclerosis

New article provides insight into cognitive fatigue in people with multiple sclerosis

Kessler Foundation researchers have authored a new article that provides insight into the factors that contribute to cognitive fatigue in individuals with multiple sclerosis (MS). The article, "Subjective cognitive fatigue in MS depends on task length," was epublished ahead of print on October 27 in Frontiers in Neurology. [More]
Twitter can indicate community's psychological well being, predict rates of heart disease

Twitter can indicate community's psychological well being, predict rates of heart disease

Twitter has broken news stories, launched and ended careers, started social movements and toppled governments, all by being an easy, direct and immediate way for people to share what's on their minds. Researchers from the University of Pennsylvania have now shown that the social media platform has another use: Twitter can serve as a dashboard indicator of a community's psychological well being and can predict rates of heart disease. [More]
MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

As flu season progresses, patients across the country continue to seek care for flu and illness symptoms at a variety of health care locations. From doctors' offices to emergency rooms, many patients find it difficult to determine the best option based on their symptoms. MedExpress physicians remind patients, that in many cases, urgent care centers offer a convenient, appropriate option for the assessment and treatment of non-severe flu or cold symptoms. [More]
New study finds link between dyspareunia and mode of delivery

New study finds link between dyspareunia and mode of delivery

Operative birth is associated with persisting pain during or after sexual intercourse, known as dyspareunia, suggests a new study published today (21 January) in BJOG: An International Journal of Obstetrics and Gynaecology. [More]
Penn State researchers explore benefits of beet juice

Penn State researchers explore benefits of beet juice

Athletes who down beet juice before exercising to increase blood flow and improve performance may be surprised at the results of a recent study conducted at Penn State's Noll Laboratory. While beetroot juice rich in nitrates did not enhance muscle blood flow or vascular dilation during exercise, researchers found that it did "de-stiffen" blood vessels under resting conditions, potentially easing the workload of the heart. [More]
Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms cluster in Parkinson’s disease patients

Nonmotor symptoms tend to appear in specific clusters in patients with Parkinson’s disease and often predate the onset of motor symptoms, research shows. [More]
GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Therapy Box releases app that allows people with limited vocal ability to use own voices

Therapy Box releases app that allows people with limited vocal ability to use own voices

The UK-based Therapy Box has released the first app that allows people who have limited vocal ability or are losing their voices due to ALS and other disabling conditions to replace generic text-to-speech synthesis with a synthesizer based on their own voice. The app breaks new ground via the integration of ModelTalker, a program developed by Tim Bunnell, PhD and colleagues at the Nemours Speech Research Laboratory in Wilmington, DE. [More]
Research findings may lead to new treatment for hypothyroidism

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective. [More]
Lack of information increases depression risk in people recovering from stroke

Lack of information increases depression risk in people recovering from stroke

People recovering from a stroke and living at home have generally a higher risk of suffering from depression. According to researchers lack of information is often a major concern for patients and this frequently contributes to their depression. This is the result of a new study from health sociologists of the University of Luxembourg. [More]
Two new ODYSSEY trials meet primary efficacy endpoints

Two new ODYSSEY trials meet primary efficacy endpoints

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints. [More]
Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

Testosterone therapy suppresses some advanced prostate cancers, find Johns Hopkins scientists

In a surprising paradox, the male hormone testosterone, generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers and also may reverse resistance to testosterone-blocking drugs used to treat prostate cancer. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
Making New Year's resolution to control diabetes

Making New Year's resolution to control diabetes

José Rodriguez often skipped breakfast and lunch only to eat a large dinner at the end of the day. Despite his erratic eating habits, Mr. Rodriguez thought he was healthy until a routine blood test revealed he had type 2 diabetes. [More]
Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval. [More]